Article

OBJECTIVES: To update the evidence-based position statement published by the
French National Authority for Health (HAS) in 2006 regarding the pharmacological
treatment of postmenopausal osteoporosis, under the auspices of the French
Society for Rheumatology and Groupe de Recherche et d'Information sur les
Osteoporoses (GRIO), and with the participation of several learned societies
(College National des Gynecologues et Obstetriciens Francais, Groupe d'Etude de
la Menopause et du Vieillissement hormonal, Societe Francaise de Chirurgie
Orthopedique, Societe Francaise d'Endocrinologie, and Societe Francaise de
Geriatrie et de Gerontologie). METHODS: A multidisciplinary panel representing
the spectrum of clinical specialties involved in managing patients with
postmenopausal osteoporosis developed updated recommendations based on a
systematic literature review conducted according to the method advocated by the
HAS. RESULTS: The updated recommendations underline the need for osteoporosis
pharmacotherapy in women with a history of severe osteoporotic fracture. In these
patients, any osteoporosis medication can be used; however, zoledronic acid is
the preferred first-line medication after a hip fracture. In patients with
non-severe fractures or no fractures, the appropriateness of osteoporosis
pharmacotherapy depends on the bone mineral density and FRAX((R)) values; any
osteoporosis medication can be used, but raloxifene and ibandronate should be
reserved for patients at low risk for peripheral fractures. Initially,
osteoporosis pharmacotherapy should be prescribed for 5 years. The results of the
evaluation done at the end of the 5-year period determine whether further
treatment is in order. CONCLUSIONS: These updated recommendations are intended to
provide clinicians with clarifications about the pharmacological treatment of
osteoporosis.
CI - Copyright (c) 2012 Societe francaise de rhumatologie. Published by Elsevier SAS.
All rights reserved.

Langue : ANGLAIS